Thyroid hormone sprayed into lungs to fight COVID ARDS? trial pulled before start

NCT ID NCT04725110

Terminated Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study planned to test whether putting a thyroid hormone (T3) directly into the lungs could help people with severe COVID-19 who need a breathing machine. The goal was to reduce fluid in the lungs and shorten time on a ventilator. However, the trial was withdrawn before any patients were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: T3 (thyroid hormone) instilled directly into the lungs
What this could lead to: If it worked, this could point toward a new way to reduce lung fluid and improve breathing in severe COVID-19 patients on ventilators.
What could go wrong: The trial was withdrawn before enrolling anyone, so no results exist. The approach is experimental and unproven in humans for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome COVID-19 severe acute respiratory syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS ARDS, HUMAN COVID19 SARS-COV INFECTION

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.